Search results
Results from the WOW.Com Content Network
Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. [10] Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. [10] Use during pregnancy may harm foetal development. [10] Leuprorelin was patented in 1973 and approved for ...
Flunixin is a nonsteroidal anti-inflammatory drug (NSAID), analgesic, and antipyretic used in horses, cattle and pigs. It is often formulated as the meglumine salt.In the United States, it is regulated by the U.S. Food and Drug Administration (FDA), and may only be lawfully distributed by order of a licensed veterinarian.
It is given by injection into a muscle. [1] Part of the dose is injected at the site of the wound. [2] Common side effects include pain at the site of injection and fever. [1] Allergic reactions including anaphylaxis may rarely occur. [1] There is also a very low risk of the spread of infections such as viral hepatitis and HIV/AIDS with the ...
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Side effects from intra-articular administration can include joint pain, swelling, lameness, and, rarely, infection of the joint. Intramuscular injection can cause dose-dependent inflammation and bleeding, since PSGAG is an analogue of the anticoagulant heparin. [4] In dogs, this may manifest as bleeding from the nose or as bloody stools. [7]
Enjoy a classic game of Hearts and watch out for the Queen of Spades!
Pituitary pars intermedia dysfunction (PPID), or equine Cushing's disease, is an endocrine disease affecting the pituitary gland of horses. It is most commonly seen in older animals, [1] and is classically associated with the formation of a long, wavy coat and chronic laminitis.
Moxidectin was approved for onchocerciasis (river-blindness) in 2018 for people over the age of 11 in the United States based on two studies. [5] There is a need for additional trials, with long-term follow-up, to assess whether moxidectin is safe and effective for treatment of nematode infection in children and women of childbearing potential. [6]